Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
Authors:
Open Access
- 10 December 2018
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 42 (3) , 463-471
Abstract
Hypersensitivity reactions (HSRs) are among the known adverse events of intravenous (i.v.) iron products. Of these, particularly severe HSRs such as anaphylaxis are of great clinical concern due to their life-threatening potential.Keywords
Funding Information
- Vifor Pharma
This publication has 31 references indexed in Scilit:
- Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency AnemiaAnemia, 2013
- Exposure to inhibitors of the renin–angiotensin system is a major independent risk factor for acute renal failure induced by sucrose‐containing intravenous immunoglobulins: a case–control studyPharmacoepidemiology and Drug Safety, 2011
- FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel DiseaseGastroenterology, 2011
- A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implicationsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North AmericaArzneimittelforschung, 2011
- Intravenous iron: From anathema to standard of careAmerican Journal of Hematology, 2008
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKDKidney International, 2005
- Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003Journal of Allergy and Clinical Immunology, 2004
- Dextran hypersensitivityImmunology Today, 1982